Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gore

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Human Gene Therapy|May 1, 1994
Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumorsP M Patel, C L Flemming, C Fisher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanomaP N Mainwaring, H Atkinson, J Chang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 9, 2003
Mucosal malignant melanoma of the head and neck: the Marsden experience over half a centuryN W Yii, T Eisen, M Nicolson, et al.
British Journal of Cancer|September 1, 1993
EPIC: an effective low toxicity regimen for relapsing lymphomaT Hickish, A Roldan, D Cunningham, et al.
European Journal of Cancer. Part B, Oral Oncology|July 1, 1994
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neckM O'Brien, J B Schofield, A Lorentzos, et al.
European Journal of Cancer. Part B, Oral Oncology|January 1, 1993
Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neckG Dadian, P G Riches, D C Henderson, et al.
British Journal of Haematology|February 1, 1989
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myelomaB C Millar, J B Bell, J A Maitland, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 6, 2001
Opportunistic infection prophylaxis in the women's interagency HIV study (WIHS)M Augenbraun, P Tarwater, R Greenblatt, et al.
Critical Care Medicine|May 1, 1993
Hemodynamic changes and circulating recombinant tumor necrosis factor-alpha concentrations in a patient undergoing isolated limb perfusionW J Fawcett, S Hill, J Sheldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancerI E Smith, B D Evans, M E Gore, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Human Gene Therapy|May 1, 1994
Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumorsP M Patel, C L Flemming, C Fisher, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanomaP N Mainwaring, H Atkinson, J Chang, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 9, 2003
Mucosal malignant melanoma of the head and neck: the Marsden experience over half a centuryN W Yii, T Eisen, M Nicolson, et al.
British Journal of Cancer|September 1, 1993
EPIC: an effective low toxicity regimen for relapsing lymphomaT Hickish, A Roldan, D Cunningham, et al.
European Journal of Cancer. Part B, Oral Oncology|July 1, 1994
The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neckM O'Brien, J B Schofield, A Lorentzos, et al.
European Journal of Cancer. Part B, Oral Oncology|January 1, 1993
Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neckG Dadian, P G Riches, D C Henderson, et al.
British Journal of Haematology|February 1, 1989
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myelomaB C Millar, J B Bell, J A Maitland, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 6, 2001
Opportunistic infection prophylaxis in the women's interagency HIV study (WIHS)M Augenbraun, P Tarwater, R Greenblatt, et al.
Critical Care Medicine|May 1, 1993
Hemodynamic changes and circulating recombinant tumor necrosis factor-alpha concentrations in a patient undergoing isolated limb perfusionW J Fawcett, S Hill, J Sheldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancerI E Smith, B D Evans, M E Gore, et al.
Pageof 16